Pipe Dreams About Apixaban for Stroke Prevention in Renal Impairment

Journal of Clinical Pharmacology

Volumn 56, Issue 5, 2016, Pages 646-647

  Stöllberger, Claudia ^a   Finsterer, Josef ^a  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

anticoagulant; apixaban; renal impairment

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN;

AGING; ATRIAL FIBRILLATION; BLEEDING; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG SAFETY; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; LETTER; PRESCRIPTION; RISK ASSESSMENT; STROKE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; HUMANS; STROKE;

EID: 84964273448     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.656     Document Type: Letter

References (5)

1. Chang M, Yu Z, Shenker A, et al., Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban [published online ahead of print 2015]. J Clin Pharmacol. 2016; 56 (5): 637-645.
2. Pathak R, Pandit A, Karmacharya P, et al., Meta-analysis on risk of bleeding with apixaban in patients with renal impairment. Am J Cardiol. 2015; 115: 323-327.
3. Jönsson KM, Wieloch M, Sterner G, et al., Glomerular filtration rate in patients with atrial fibrillation on warfarin treatment: a subgroup analysis from the AURICULA registry in Sweden. Thromb Res. 2011; 128: 341-345.
4. Stöllberger C, Finsterer J,. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban. Herz. 2015; 40 (Suppl 2): 140-145.
5. Lammers LA, Achterbergh R, de Vries EM, et al., Short-term fasting alters cytochrome P450-mediated drug metabolism in humans. Drug Metab Dispos. 2015; 43: 819-828.